Abstract
Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Current HIV Research
Title:A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir
Volume: 12 Issue: 5
Author(s): Bawneet K. Narang, Gurpreet K. Grewal, Subhajit Roy, Jitender Bariwal, Manish K. Gupta and Ravindra K. Rawal
Affiliation:
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Abstract: Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Export Options
About this article
Cite this article as:
Narang K. Bawneet, Grewal K. Gurpreet, Roy Subhajit, Bariwal Jitender, Gupta K. Manish and Rawal K. Ravindra, A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140807150753
DOI https://dx.doi.org/10.2174/1570162X12666140807150753 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Challenges and Discoveries in Polypharmacology of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry 3D-QSAR, Topomer CoMFA, Docking Analysis, and ADMET Predictio n of Thioether Pleuromutilin Derivatives as Antibacterial Agents
Letters in Drug Design & Discovery Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds Pro-Oxidant Natural Products as Anticancer Agents
Current Drug Targets Synergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Current Medicinal Chemistry Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Hyaluronic Acid: Targeting Immune Modulatory Components of the Extracellular Matrix in Atherosclerosis
Current Medicinal Chemistry The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antileishmanial Drug Discovery: Synthetic Methods, Chemical Characteristics, and Biological Potential of Quinazolines and its Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Thematic Issue: Patent Ductus Arteriosus in Extremely Premature Neonates)
Current Pediatric Reviews Potential Contribution of Action of Renin Angiotensin System to Bone Metabolism
Current Hypertension Reviews Anti-inflammatory Cytokines and Cytokine Antagonists
Current Pharmaceutical Design Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews Novel Therapeutics in Glaucoma Management
Current Neuropharmacology The Immune System in Cancer Prevention, Development and Therapy
Anti-Cancer Agents in Medicinal Chemistry Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety